Previous close | 5.65 |
Open | 5.95 |
Bid | 5.65 |
Ask | 6.35 |
Strike | 17.50 |
Expiry date | 2025-01-17 |
Day's range | 5.95 - 5.95 |
Contract range | N/A |
Volume | |
Open interest | 764 |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.